Abstract
Cancer poses a significant global health burden, aligning conventional therapies limited by poor drug bioavailability, systemic toxicity, and the development of chemoresistance. The aligning challenges have showcased the growing interest in natural bioenhancers, which are capable of improving therapeutic efficacy while mitigating adverse effects. Cow urine distillate (CUD), a traditional Ayurvedic preparation that is derived from Bos indicus, holds impressive research data in terms of immunomodulatory, antioxidant, and bioavailability-enhancing properties. CUD constitutes phytochemicals like ferulic acid, cinnamic acid, and phenylethanol, and cinnamic acid shows favorable binding affinities in docking studies performed with in silico tools like AutoDock Vina, Schrödinger Glide, and Molecular Operating Environment. As the research literature indicates, molecular dynamics simulations show a stable ligand receptor with reported minimal conformational fluctuation. The in silico investigations has revealed the potential of CUD derived phytochemicals as adjuvants in oncology with the primary cancer associated molecular targets including Cyclin dependent kinases, DNA topoisomerase II, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), protein kinase B (Akt), Bcl-2, and matrix metalloproteinases are widely researched and explored using high-resolution structures from the Protein Data Bank. In silico ADMET profiling ensured by SwissADME and pkCSM gives good oral absorption, drug-likeness, and low predicted toxicity, supporting translational feasibility. Network pharmacology analyses have reported multi-target modulation of pathways controlling apoptosis, proliferation, angiogenesis, inflammation, immune response, and therapeutic resistance. Computational insights give the rationale for the mechanism for CUD as a multitarget natural bioenhancer. Showing the need for systematic in vitro, in vivo, and clinical studies to validate its bioenhancing and adjunctive potential in cancer therapeutics.

This publication has 37 references indexed in Scilit: